Feasibility and Safety of Ex Vivo Delivery of Rituximab to Lung Allografts in Transplant Recipients at High Risk for Epstein-Barr Virus-associated Posttransplant Lymphoproliferative Disorder.

Background: Ex vivo lung perfusion (EVLP) offers a novel platform for delivering targeted therapies directly to donor lungs before transplantation, potentially reducing systemic side effects. Our study evaluated the feasibility and safety of rituximab delivery to donor lungs from Epstein-Barr virus (EBV)-seropositive donors for transplantation into EBV-seronegative recipients (D Methods: A pilot study was conducted involving 5 EBV-seronegative lung transplant recipients. Donor lungs were perfused with 500 mg rituximab during EVLP for 3-4 h. Primary outcomes included safety and feasibility, assessed by monitoring lung function during perfusion, posttransplant complications, and graft dysfunction. Secondary outcomes included EBV DNAemia, PTLD incidence, peripheral B-cell frequencies, EBV blood transcripts, and rituximab serum levels. Results: Rituximab delivery via EVLP was feasible and safe, with no significant deviations in lung function or adverse events linked to treatment. One patient experienced primary graft dysfunction. Peripheral B-cell counts were reduced immediately posttransplant and remained low in some patients, whereas others rebounded over the weeks posttransplant, and serum rituximab levels were undetectable after 2 wk. Three patients developed EBV DNAemia and 2 developed PTLD within 2 y, although PTLD lesions were not observed in transplanted lungs. Conclusions: EVLP-based rituximab delivery is a feasible and promising strategy for targeting donor-transmitted EBV with minimal systemic exposure. Although the findings suggest potential clinical benefit, the development of PTLD in extrathoracic sites underscores the need for further optimization and larger studies to evaluate efficacy and refine the intervention.